Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 7.09 5.51% 0.37
SYRS closed up 5.51 percent on Monday, May 20, 2019, on 47 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical SYRS trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Bollinger Band Squeeze Range Contraction 5.51%
Outside Day Range Expansion 5.51%
Bollinger Band Squeeze Range Contraction 4.42%
Narrow Range Bar Range Contraction 4.42%

Older signals for SYRS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Biopharmaceutical Cancer Diseases Disease Medication Leukemia Refractory Acute Myeloid Leukemia Immune Mediated Diseases Acute Leukemia High Risk Myelodysplastic Syndrome
Is SYRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.73
52 Week Low 5.17
Average Volume 215,064
200-Day Moving Average 8.2
50-Day Moving Average 7.6958
20-Day Moving Average 6.91
10-Day Moving Average 6.82
Average True Range 0.4251
ADX 18.66
+DI 18.036
-DI 18.6227
Chandelier Exit (Long, 3 ATRs ) 6.1647
Chandelier Exit (Short, 3 ATRs ) 7.6453
Upper Bollinger Band 7.2818
Lower Bollinger Band 6.5382
Percent B (%b) 0.74
BandWidth 10.761216
MACD Line -0.1778
MACD Signal Line -0.2178
MACD Histogram 0.04
Fundamentals Value
Market Cap 186.18 Million
Num Shares 26.3 Million
EPS -2.11
Price-to-Earnings (P/E) Ratio -3.36
Price-to-Sales 289.82
Price-to-Book 4.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.02
Resistance 3 (R3) 7.93 7.54 7.87
Resistance 2 (R2) 7.54 7.30 7.58 7.81
Resistance 1 (R1) 7.31 7.15 7.43 7.40 7.76
Pivot Point 6.92 6.92 6.97 6.96 6.92
Support 1 (S1) 6.69 6.68 6.81 6.78 6.42
Support 2 (S2) 6.30 6.53 6.34 6.37
Support 3 (S3) 6.07 6.30 6.32
Support 4 (S4) 6.16